Medical diagnostics firm Kypha has acquired diagnostics platform and contract development firm, Biosensia for an undisclosed sum.
Part of the NovaUCD innovation community, Biosensia is engaged in the development manufacturing and commercialization of RapiPlex platform and tests.
Kypha CEO Chad Stiening said: “The proprietary technologies and core competencies of each company are perfectly synergistic. Blending them enhances and accelerates the delivery of our products to health care practitioners, researchers and pharmaceutical companies seeking to more precisely assess and monitor immune status dynamics.”
RapiPlex is a point-of-care diagnosis system based on a set of technologies that can produce quantitative and qualitative laboratory quality test results.
The diagnosis system includes disposable assay cartridge and small table top instrument, which will facilitate near patient care with better analytical performance.
RapiPlex, which will support CLIA-waived protocols, produces laboratory quality quantitative and qualitative results with a disposable cartridge for up to 24 analytes in a multiplex format.
The system also helps in high sensitive fluorescence detection, and is also compatible with whole blood, plasma, serum, urine, saliva and milk.
Biosensia is also expertise in immunology, biochemistry, microfluidics, design engineering, manufacturing and quality/regulatory affairs.
In addition, the firm provides contract assay development and manufacturing services to its customers.
Biosensia chief operating officer Niamh O’Luanaigh said: “We are very excited about bringing our advanced platform together with Kypha’s specialized biomarker testing and achieving the clinical impact that we designed RapiPlex to fulfill.”
Kypha is involved in the development of specialized biomarker testing solutions for precision monitoring of immune status and inflammation.
The company’s Comp act testing platform is comprised of small portable instrument with multiple single-use rapid assay cassettes, which help to quantitatively measure Complement activation biomarkers ranging from a small volume of blood in either laboratory or point-of-care settings.
RapiPlex, which will support CLIA-waived protocols, can produce laboratory quality quantitative and qualitative results with a disposable cartridge for up to 24 analytes in a multiplex format.